{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:31:45Z","timestamp":1771601505395,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adolescents and young adults (AYA) surviving classical Hodgkin lymphoma (cHL) risk long term fatal treatment\u2010related toxicities. We utilized the Surveillance, Epidemiology and End Results (SEER) program to compare excess mortality rate (EMR\u2010observed minus expected mortality) for 10\u2010year survivors of AYA cHL diagnosed in 1973\u20131992 and 1993\u20132003 eras. The 15\u2010year EMR reduced from 4.88% to 2.19% while the 20\u2010year EMR reduced from 9.46% to 4.07% between eras. Survivors of stages 1\u20132 had lower EMR than survivors of stages 3\u20134 cHL in the 1993\u20102003 but not in the 1973\u20131992 era. There was an overall decline in risk of death between 10 and 15 years from diagnosis, driven mostly by second neoplasms and cardiovascular mortality. Despite reduction in fatal second neoplasms and cardiovascular disease with more current therapy, long term survivors of AYA cHL still have a higher risk of death than the general population highlighting the need for safer therapies.<\/jats:p>","DOI":"10.1002\/ajh.24964","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T08:45:52Z","timestamp":1510130752000},"page":"238-245","source":"Crossref","is-referenced-by-count":14,"title":["Excess mortality among 10\u2010year survivors of classical Hodgkin lymphoma in adolescents and young adults"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3659-3798","authenticated-orcid":false,"given":"Ana C.","family":"Xavier","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics Children's of Alabama\/University of Alabama at Birmingham Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine The Ohio State University  Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics Children's Hospital of Michigan\/Wayne State University School of Medicine Detroit Michigan"},{"name":"Molecular Therapeutics Program Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine Detroit Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine University of Alabama at Birmingham Birmingham Alabama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-115493"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.0693"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv018"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-579193"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278796"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.1.47.47"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/865870"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0064"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510795"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841869009090053"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.131"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(90)90221-5"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/8.suppl_1.S115","article-title":"Hodgkin's disease: complications of therapy and excess mortality","volume":"8","author":"Hoppe RT.","year":"1997","journal-title":"Ann Oncol."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009065830"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.021"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.005"},{"issue":"5","key":"e_1_2_6_18_1","first-page":"27","article-title":"Results of the EORTC\u2010GELA H9 randomized trials: the H9\u2010F trial (comparing 3 radiation dose levels) and H9\u2010U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL)","volume":"92","author":"Thomas J","year":"2007","journal-title":"Haematologica."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.2.207"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.1.27"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034405"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505949"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.5791"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03564.x"},{"key":"e_1_2_6_25_1","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","author":"Nimwegen FA","year":"2017","journal-title":"Blood."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.1180"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024811"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0424"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.3205"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.7511"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182a88099"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24964","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:13:59Z","timestamp":1694715239000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/ajh.24964"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24964","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]}}}